5DPV image
Entry Detail
PDB ID:
5DPV
Keywords:
Title:
Aurora A Kinase in Complex with AA35 and JNJ-7706621 in Space Group P6122
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2015-09-14
Release Date:
2016-07-20
Method Details:
Experimental Method:
Resolution:
2.29 Å
R-Value Free:
0.27
R-Value Work:
0.22
R-Value Observed:
0.22
Space Group:
P 61 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Aurora kinase A
Mutations:T287A
Chain IDs:A
Chain Length:273
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2.
Sci Rep 6 28528 28528 (2016)
PMID: 27339427 DOI: 10.1038/srep28528

Abstact

The essential mitotic kinase Aurora A (AURKA) is controlled during cell cycle progression via two distinct mechanisms. Following activation loop autophosphorylation early in mitosis when it localizes to centrosomes, AURKA is allosterically activated on the mitotic spindle via binding to the microtubule-associated protein, TPX2. Here, we report the discovery of AurkinA, a novel chemical inhibitor of the AURKA-TPX2 interaction, which acts via an unexpected structural mechanism to inhibit AURKA activity and mitotic localization. In crystal structures, AurkinA binds to a hydrophobic pocket (the 'Y pocket') that normally accommodates a conserved Tyr-Ser-Tyr motif from TPX2, blocking the AURKA-TPX2 interaction. AurkinA binding to the Y- pocket induces structural changes in AURKA that inhibit catalytic activity in vitro and in cells, without affecting ATP binding to the active site, defining a novel mechanism of allosteric inhibition. Consistent with this mechanism, cells exposed to AurkinA mislocalise AURKA from mitotic spindle microtubules. Thus, our findings provide fresh insight into the catalytic mechanism of AURKA, and identify a key structural feature as the target for a new class of dual-mode AURKA inhibitors, with implications for the chemical biology and selective therapeutic targeting of structurally related kinases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures